ReviewCurrent hematologic malignancy reports2009
Natural killer-cell neoplasms.
Review in Current hematologic malignancy reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Crescentic glomerulonephritis associated with NK-large granular lymphocytic leukemia: A case report.Medicine · 2025Article
- Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine.Diagnostics (Basel, Switzerland) · 2022Review
- [Outcome of haploidentical hematopoietic stem cell transplantation for aggressive natural killer cell leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2021Article
- Prognostic Nutritional Index, Another Prognostic Factor for Extranodal Natural Killer/T Cell Lymphoma, Nasal Type.Frontiers in oncology · 2020Article
- Cutaneous EBV-related lymphoproliferative disorders.Seminars in diagnostic pathology · 2017Article
- A TNM Staging System for Nasal NK/T-Cell Lymphoma.PloS one · 2015Article
- Statins inhibit proliferation and cytotoxicity of a human leukemic natural killer cell line.Biomarker research · 2013Article
- Aggressive mature natural killer cell neoplasms: from epidemiology to diagnosis.Orphanet journal of rare diseases · 2013Review
- Lymphomatoid granulomatosis presenting with gingival involvement in an immune competent elderly male.Head and neck pathology · 2012Article
- EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.Leukemia · 2012Article
- Extranodal nasal-type NK/T-cell lymphoma of the palate and paranasal sinuses.The American journal of case reports · 2012Article
- Treatment of Aggressive NK-Cell Leukemia: A Case Report and Review of the Literature.Case reports in hematology · 2011Article
- Blastic natural killer cell lymphoma/leukaemia in a cat.JFMS open reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The natural killer (NK)-cell neoplasms are rare, representing less than 1% of non-Hodgkin lymphoma, except in Asia and Latin America, where they represent 3% to 6%. NK-cell neoplasms include immature acute leukemias; a blastic NK-cell lymphoma, which is obsolete because of its plasmacytoid dendritic-cell origin; and mature NK neoplasms, comprising extranodal NK/T-cell lymphoma (ENKL), nasal-type; aggressive NK-cell leukemia; and chronic NK-cell lymphoproliferative disorders, which are often reactive. Epstein-Barr virus is usually detected in tumor cells of ENKL and aggressive NK-cell leukemia. The latter two mature NK neoplasms are relatively chemoresistant because of the frequent expression of P-glycoprotein. Early radiation is advocated for localized nasal ENKL. Stem cell transplantation is recommended for advanced disease, owing to a poor prognosis. Novel agents, including chemotherapy, inhibitors of molecular pathways, and monoclonal antibodies, are under investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.